Aktienanalyse zu Mirum Pharmaceuticals Inc (MIRM)MIRMMirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Mirum Pharmaceuticals Inc is not a strong buy. The stock is priced at $80.14, which is significantly below the analyst price targets ranging from $130 to $200, indicating potential upside. However, the RSI is at 38.321, suggesting the stock is in a bearish trend, and the forward P/E ratio is extremely high at 166.67, indicating overvaluation concerns. The main risk is the recent negative net income of -790.15 million in Q1 2026, which raises concerns about the company's financial health.